Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Non-Current Debt (2016)

Corcept Therapeutics (CORT) has disclosed Non-Current Debt for 5 consecutive years, with $3.7 million as the latest value for Q2 2016.

  • Quarterly Non-Current Debt fell 80.7% to $3.7 million in Q2 2016 from the year-ago period, while the trailing twelve-month figure was $3.7 million through Jun 2016, down 80.7% year-over-year, with the annual reading at $12.5 million for FY2015, 48.79% down from the prior year.
  • Non-Current Debt hit $3.7 million in Q2 2016 for Corcept Therapeutics, down from $8.7 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $30.2 million in Q2 2013 to a low of $3.7 million in Q2 2016.
  • Historically, Non-Current Debt has averaged $22.8 million across 5 years, with a median of $26.8 million in 2014.
  • Biggest five-year swings in Non-Current Debt: increased 6.41% in 2013 and later tumbled 80.7% in 2016.
  • Year by year, Non-Current Debt stood at $29.0 million in 2012, then increased by 1.01% to $29.3 million in 2013, then dropped by 16.57% to $24.5 million in 2014, then crashed by 48.79% to $12.5 million in 2015, then plummeted by 70.11% to $3.7 million in 2016.
  • Business Quant data shows Non-Current Debt for CORT at $3.7 million in Q2 2016, $8.7 million in Q1 2016, and $12.5 million in Q4 2015.